| Document |
Document Title |
|
WO/2018/012578A1 |
The present invention addresses the problem of providing a novel, safe, and side-effect-free ghrelin secretion promotor capable of enhancing the ghrelin secretory function present in the human body, wherein the promotor is provided in th...
|
|
WO/2018/011015A1 |
The present invention relates to a low-dosed oral dosage form for treatment and/or prophylaxis of diseases, especially of endometriosis, polycystic ovary syndrome and/or atopic dermatitis. More particularly, the present invention concern...
|
|
WO/2018/006688A1 |
Provided in the present invention is a use of a fulvestrant in the preparation of drugs for treating the growth hormone adenoma. By means of the technical solution, the present invention can effectively improve the prognosis of patients ...
|
|
WO/2018/001232A1 |
The present invention relates to an acrylic acid-based derivative as represented by a general formula (I), stereoisomers and tautomers thereof, or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutica...
|
|
WO/2018/003997A1 |
The present invention addresses the problem of providing a safe and easy-to-prepare cell preparation for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a cell preparation for prevention and/or treatment...
|
|
WO/2018/005193A1 |
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...
|
|
WO/2017/223457A1 |
A population of Brown adipose tissue (BAT) cells generated from embryonic stem cells (ES) or induced pluripotent stem cells (iPS), called iBAT, the use thereof, methods to obtain iBAT by directed differentiation of ES/iPS, and media comp...
|
|
WO/2017/215602A1 |
Provided in the present invention is a use of doxycycline in the preparation of a medicine for treating or preventing aging diseases, wherein the doxycycline is administered at a dose of less than 2 μg/ml, and the aging diseases mainly ...
|
|
WO/2017/211330A1 |
15β-substituted derivatives of estrone of general formula I wherein R1, R2, R3, R4, R5 are independently selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, C1-C4 halogenalkyl, halogen, COOR6 wherein R6 is C1-C4 alkyl; H, ...
|
|
WO/2017/211293A1 |
The present invention relates to a crystalline form of a succinate used as a dipeptidyl peptidase-4 inhibitor, and a manufacturing method, pharmaceutical composition, and application thereof. The invention specifically relates to a dipep...
|
|
WO/2017/213268A1 |
The purpose of the invention is to provide an insulin secretion promoter having an action that effectively promotes insulin secretion, an insulin sensitizer having an action that effectively improves insulin resistance, an agent for prev...
|
|
WO/2017/208076A1 |
Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patien...
|
|
WO/2017/208847A1 |
A pharmaceutical composition including 4.5-10.0 mass% of fulvestrant relative to the total mass of the pharmaceutical composition, 8-23 mass% of at least one polyhydric alcohol selected from propylene glycol and 1,3-butylene glycol relat...
|
|
WO/2017/206827A1 |
Disclosed are a crystal form of an L-proline cocrystal of a sodium-glucose cotransporter 2 inhibitor, a preparation method therefor, and a pharmaceutical composition and a use therof. Particularly involved are the crystal form of the L-p...
|
|
WO/2017/204277A1 |
The present invention provides an anti-TGF-beta3 antibody and a method of using the antibody. The anti-TGF-beta3 antibody according to the present invention has a binding activity to TGF-beta3 but does not have a neutralizing activity to...
|
|
WO/2017/197904A2 |
A plurality of new crystal forms I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII and XIV of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-
2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, as well as a preparation method and med...
|
|
WO/2017/193824A1 |
An artemisinin analog as represented by formula (A) and application thereof in preparing a pharmaceutical product for promoting lipid catabolism and/or prevention or treatment of metabolism-related disease. The artemisinin analog promote...
|
|
WO/2017/194030A1 |
A use for the protein function inhibitor DAPT in preparing medicine for treating endocrine diseases is provided in the present invention. By means of the technical solution, the present invention allows for effective amelioration of endo...
|
|
WO/2017/195901A1 |
Disclosed are a screening method for drugs for the treatment of obesity-related diseases using as the indicator the ability of a candidate drug to inhibit the action of pentraxin 4 and a pharmaceutical composition for treating obesity-re...
|
|
WO/2017/186793A1 |
The invention relates to chemical compounds that are useful in the treatment of a subject afflicted by a thyroid disease, in particular to compounds that exhibit activity as thyroid-stimulating hormone receptor (TSHR) antagonists and the...
|
|
WO/2017/187375A1 |
A composition for the treatment of polycystic ovary syndrome, as well as the endocrine-gynecological and metabolic disorders associated therewith are described. In particular, the composition of the invention comprises inositol and extra...
|
|
WO/2017/181277A1 |
Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also des...
|
|
WO/2017/184811A1 |
A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or...
|
|
WO/2017/179744A1 |
The present invention relates to: a pharmaceutical composition for preventing and treating diseases caused by the excessive release of steroid hormones, containing a pyruvate dehydrogenase kinase 4 (PDK4) activity inhibitor as an active ...
|
|
WO/2017/180174A1 |
The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a Salvia extract. The compositions are useful for, for example,...
|
|
WO/2017/175509A1 |
Provided is a means that is effective in bone regeneration or bone augmentation. A porous composite including octacalcium phosphate and parathyroid hormone.
|
|
WO/2017/175066A1 |
The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
|
|
WO/2017/172957A1 |
Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for tr...
|
|
WO/2017/164208A1 |
Provided is a medicinal composition for treating a renal disease. The medicinal composition for treating a renal disease comprises a mineral corticoid receptor antagonist.
|
|
WO/2017/159540A1 |
The purpose of the present invention is to provide a drug containing as the active ingredient a persistent human growth hormone preparation having suppressed prolactin-like activity and a longer half-life in the blood than 22 K human gro...
|
|
WO/2017/148883A1 |
The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.
|
|
WO/2017/151728A1 |
Provided herein are compositions, systems, kits, and methods of indirectly assessing insulin release in a cell.
|
|
WO/2017/150477A1 |
The purpose of the present invention is to provide a compound having an excellent JAK1-inhibiting activity. The compound according to the present invention has a JAK1-inhibiting activity, and therefore has an immunesuppressing effect, an...
|
|
WO/2017/150548A1 |
This peptide has an amino acid sequence NKNPFLFGSNR (SEQ ID NO: 1) at the N terminus thereof.
|
|
WO/2017/148977A1 |
This invention concerns Selective Progesterone Receptor Modulators (SPRM) in a prodrug form as well as their application in therapy. (3α, 11β,17β)-1 1-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-
diene-3,17-diol (Compoun...
|
|
WO/2017/146053A1 |
Provided are: pharmaceutical composition particles and an orally disintegrating tablet including the same which are capable of achieving both the masking of unpalatable taste and an improvement in elution properties; and a method for pro...
|
|
WO/2017/141106A1 |
The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are ...
|
|
WO/2017/134188A1 |
The present invention is directed to novel compounds of Formula I; pharmaceutically acceptable salts or solvates thereof, and their use.
|
|
WO/2017/133057A1 |
The present invention relates to the field of medicines, and particularly to a schisandra lignan compound or applications of pharmaceutically acceptable salt, hydrate or a prodrug of thereof in the preparation of an FXR transcriptional a...
|
|
WO/2017/129639A1 |
The present invention relates to a nutritional composition comprising at least one human milk oligosaccharide for use in preventing and/or treating a health disorder in an infant or young child by increasing GLP-1 in said infant or young...
|
|
WO/2017/108752A1 |
The present invention relates to an improved crystallization procedure to obtain canagliflozin hemihydrate crystals having a narrow particle size distribution by removing a small part of the crystalline suspension in the crystallization ...
|
|
WO/2017/107945A1 |
The present invention relates to a crystalline form of benzoate of a dipeptidyl peptidase-IV inhibitor, a method for preparing the same, a pharmaceutical composition,and a use thereof. Specifically, the present invention relates to a cry...
|
|
WO/2017/106974A1 |
Two isoforms of thyroid receptor alpha (THRα1 and THRα2) have been found to be associated with the growth of cancer. Use of inhibitors of THRα1 (Formula I) and/or agonists of THRα2 (Formula II) in the treatment of such cancers is dis...
|
|
WO/2017/106381A1 |
An insulin analogue comprises an insulin B-chain polypeptide sequence containing a 3-iodo-Tyrosine or (3,5)-di-iodo-Tyrosine at position B26 relative to the positions of a wild type insulin B chain and may additionally comprise a substit...
|
|
WO/2017/106814A1 |
Methods and compositions are provided for treating and preventing preterm labor using liposome encapsulated tocolytic agents, such as indomethacin. In certain aspects, targeted liposomes are provided that allow delivery of tocolytic agen...
|
|
WO/2017/100896A1 |
The present disclosure concerns non-agglomerating bioconjugates of amylin, amylin-mimetic compounds, and combinations comprising the same, wherein said bioconjugate contains at least one acyl unit. Methodology of making and using are pro...
|
|
WO/2017/100062A1 |
Aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents. More particularly, aspects described herein relate to improved methods for infusing food and beverage composit...
|
|
WO/2017/095261A1 |
The invention relates to the pharmaceutical industry and can be used for producing medicinal agents required in the treatment of diseases of the organs of the reproductive system (conditions of the mammary gland, womb, endometrium). A me...
|
|
WO/2017/094743A1 |
An agent for the treatment and/or prevention of conditions associated with hyperglucocorticoidemia, characterized in containing as an active ingredient a compound indicated by formula (I): (where ring A is (II), ring B is a substituted o...
|
|
WO/2017/088830A1 |
Provided is an in vitro orientation-induced differentiation method for differentiating human induced pluripotent stem cells (hiPS) into leydig cells (LCs) by means of neural crest stem cells (NCSCs).
|
